Page 19 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer. Design Scandinavian cohort study. Setting Denmark, Norway, and Sweden, 2007-21. Participants Patients who started GLP1 receptor agonist treatment were compared with patients who started dipeptidyl peptidase 4 (DPP4) inhibitor treatment, and in an additional analysis, patients who started sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment. Main outcome measures Thyroid cancer identified from nationwide cancer registers. An active-comparator new user study design was used to minimise risks of confounding and time related biases from using real world studies of drug effects. Cox regression was used to estimate hazard ratios, controlling for potential confounders with propensity score weighting. Results The mean follow-up time was 3.9 years (standard deviation 3.5 years) in the GLP1 receptor agonist group and 5.4 years (standard deviatio

United statesKarolinska institutetEli lillyDrottning victorias frimurarestiftelseKonung gustafSwedish research councilEuropean medicines agencyLundbeck foundationDrug administrationDanish cancer societySwedish cancer societyBoehringer ingelheimNovo nordisk foundationWorld health organizationResearch foundation denmarkNovo nordisk